NCT04954014View on ClinicalTrials.gov

Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
ARDS, HumanCoronavirus Infection
Interventions
DRUG

Bevacizumab

Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.

DRUG

BAT

Patients will receive best available treatment for COVID-19.

Trial Locations (1)

14004

Hospital Universitario Reina Sofía, Córdoba

Sponsors
All Listed Sponsors
lead

Maimónides Biomedical Research Institute of Córdoba

OTHER